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Dent’s disease is an X-linked recessive disorder affecting the
proximal tubules and is frequently associated with mutations
in CLCN5, which encodes the electrogenic chloride-proton
exchanger ClC-5. To better understand the functional
consequences of CLCN5 mutations in this disease, we
screened four newly identified missense mutations (G179D,
S203L, G212A, L469P), one new nonsense mutation (R718X),
and three known mutations (L200R, C219R, and C221R), in
Xenopus laevis oocytes and HEK293 cells expressing either
wild-type or mutant exchanger. A type-I mutant (G212A)
trafficked normally to the cell surface and to early
endosomes, underwent complex glycosylation at the cell
surface like wild-type ClC-5, but exhibited significant
reductions in outwardly rectifying ion currents. The type-II
mutants (G179D, L200R, S203L, C219R, C221R, L469P, and
R718X) were improperly N-glycosylated and were non-
functional due to retention in the endoplasmic reticulum.
Thus these mutations have distinct mechanisms by which
they could impair ClC-5 function in Dent’s disease.
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Dent’s disease is a heterogeneous group of X-linked inherited
disorders that have in common a renal phenotype consisting
mainly of the urinary loss of low-molecular-weight protein,
hypercalciuria, nephrocalcinosis, and progressive renal fail-
ure, all of which are sometimes associated with other
proximal tubule dysfunctions. Inactivating mutations of
CLCN5 are present in approximately two-thirds of patients,
whereas mutations of OCRL1, a gene encoding a Phospho-
Inositide (PI) phosphatase, have been reported in only a few
cases.1,2
CLCN5 encodes ClC-5, an electrogenic Cl/Hþ exchan-
ger.3,4 In the kidney, ClC-5 is predominantly expressed in the
proximal tubule and a-intercalated cells of the collecting
duct. Lower levels are also expressed in the thick ascending
limb of Henle’s loop.5,6 In proximal tubule cells, ClC-5 is
present on the membranes of intracellular subapical vesicles,
in which it colocalizes with the v-type Hþ -ATPase, markers
of early endosomes and proteins that have just been
internalized by endocytosis.5–9 This suggests that ClC-5 may
neutralize currents of vesicular Hþ -ATPases and that ClC-5
loss-of-function could lead to the defective endocytosis
observed in the syndrome by impairing the crucial step of
endosomal acidification.6,10–12 ClC-5 disruption also led to a
trafficking defect of megalin and its co-receptor cubilin.10,13
Furthermore, ClC-5 may also contribute to protein–protein
interactions required for receptor-mediated endocytosis at
the proximal tubule cell surface as a result of its binding with
cofilin,14 an actin-depolymerizing protein, the PDZ-domain
protein NHERF2,15 and Nedd-4,16 which by ubiquitinating
ClC-5 at its PY motif may shuttle it from the cell surface into
early endosomes. Thus, as a whole, the mechanisms by which
ClC-5 dysfunction results in Dent’s disease still remain largely
unknown.
Despite the large number of CLCN5 mutations already
reported, there has so far been only two reports providing a
full functional analysis of some ClC-5 mutations.17,18 Here,
we report data that help to shed more light on the functional
implications of ClC-5 in Dent’s disease by describing five new
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and three previously reported CLCN5 mutations, and
investigating their consequences in X. laevis oocytes and
HEK293 in terms of electrical activity, protein trafficking,
expression, and subcellular localization.
RESULTS
Clinical data from patients carrying the previously un-
reported mutations are shown in Table 1. All these patients
presented with low-molecular-weight-proteinuria, hypercal-
ciuria and/or nephrocalcinosis, and at least one other
renal proximal tubular defect (glycosuria, aminoaciduria,
phosphaturia).
To characterize the CLCN5 mutations, we injected the
corresponding human ClC-5 mutants and wild-type (WT)
ClC-5 cRNA into oocytes. Two-electrode voltage-clamp
recordings revealed strongly outwardly rectifying currents
from the oocytes expressing WT ClC-5, as previously
reported (Figure 1a-b).3,4,19,20 The currents for the G212A
mutant were significantly reduced by 56% (n¼ 18) by
comparison to oocytes expressing WT ClC-5 (Figure 1a).
Despite reduced current amplitude, the voltage dependence
of the currents for the G212A mutant resembled those of WT
ClC-5 (Figure 1). In good agreement with a residual ClC-5
activity, currents from this mutant were reduced with partial
replacement of extracellular Cl by I, an anion for which
WT ClC-5 has lower permeability (data not shown).19 In
contrast, we failed to record any currents with the G179D
(n¼ 26), S203L (n¼ 6), C219R (n¼ 22), L469P (n¼ 14),
R718X (n¼ 13) mutants (Figure 1a). The L200R (n¼ 7) and
C221R (n¼ 22) mutants were also found to be non-
functional, as already reported.18,21
To further elucidate the mechanisms leading to reduced
currents, we then investigated the cell-surface targeting of
Table 1 | Clinical and biochemical abnormalities in probands with Dent syndrome and new CLCN5 mutations
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age at first symptom (years) 4 8 7 3 4 1
Failure to thrive + — — — — —
LMWP + + + + + +
Hypercalciuria + — + + + +
Renal impairment +a — — — — +
Nephrocalcinosis + — + +b + +
Nephrolithiasis — — — — — —
Phosphate diabetes + + NA — — —
Rickets + — — — — —
Aminoaciduria + — NA NA — +
Glycosuria NA NA NA — — —
Hypouricemia NA NA NA NA + +
Polyuria + — — — — —
Country Portugal Portugal Belgium North Africa France France
Mutation
Nucleotide c.1406T4C c.635G4A c.2152C4T c.536G4A c.608C4T
Protein p.Leu469Pro p.Gly212Ala p.Arg718X p.Gly179Asp p.Ser203Leu
LMWP, low-molecular-weight-proteinuria; NA, not available; +, present; , absent.
aRenal function impairment at 10 years.
bNephrocalcinosis at 12 years. Numbering is according to the cDNA sequence (GenBank entry NM 000084). The A of the ATG of the initiator methionine codon is denoted as
nucleotide 1. Patients 1 and 2 are brothers.
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Figure 1 | Electrophysiological properties of WT and mutant
ClC-5. (a) Steady-state current-voltage relationships obtained in
ND96 solution (pH 7.4). Each data point represents the
mean±s.e.m. for at least six oocytes from three different oocyte
batches. NI, non-injected oocytes. (b) Representative original
voltage-clamp recordings obtained from oocytes expressing WT
CLC-5, G179D mutant CLC-5, and from non-injected oocytes
under the same conditions as described in panel a. WT, wild-type
oocytes.
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WT and mutant ClC-5 proteins. The normalized chemilu-
minescence signals for the G212A mutant were not different
from those of WT ClC-5, indicating that there was no
impairment of cell-surface expression with this mutant
(Figure 2). These findings suggested that the significant decrease
in current amplitudes for the G212A mutant (Figure 1a-b and
Figure 2) were not due to impairment in protein trafficking to
the cell surface. This could be explained by changes in
conductance or in the regulation of the mutant proteins. In
contrast, the normalized chemiluminescence signals for the
G179D, L200R, S203L, C219R, L469P, and R718X mutants were
not different from those observed in non-injected oocytes. No
surface expression was detected with the C221R mutant, as
already shown.18 The absence of significant electrical activity in
oocytes carrying these mutants could be explained by an
impairment of cell-surface expression due to a mis-targeting
(Figure 1a-b, Figure 2) or by altered protein expression.
Total cell lysates isolated from oocytes expressing either
WT or mutant ClC-5 were subjected to a western blot analysis
(Figure 3a). In the lane loaded with WT ClC-5, a
B90–100 KDa diffuse immunoreactive band was detected,
consistent with data already reported.10 On the one hand,
when an equivalent amount of proteins was loaded in each
lane, no significant difference in density or size could be
detected between WT ClC-5 and the G212A mutant. Thus,
the decreased currents of the G212A mutant were not
attributable to different protein expression levels. On the
other hand, expression of the G179D, L200R, S203L, C219R,
and L469P mutants was reduced compared with WT ClC-5.
This could be explained by a change in the processing of the
mutant proteins. The C221R mutant also showed this
reduced protein expression, which conflicted with previously
published data.18 The R718X mutant showed a band smaller
than those of WT ClC-5, as would be expected for the
truncation mutation, and the protein abundance was lower
than that of WT ClC-5.
The diffuse immunoreactive band observed with WT ClC-5
at B90–100 kDa suggested that hClC-5 may have undergone
post-translational modification, as previously described.22 To
gain more insight into the processing of WT and mutant forms
of ClC-5, total cell lysates were treated with the Endo H and
PNGase F (Figure 3b and c). Endo H cleaves high-mannose
glycosylations, and some hybrid oligosaccharides form of
N-linked glycoproteins. Therefore, Endo H-sensitive proteins
likely remain in the endoplasmic reticulum without further
processing, and are only core-glycosylated. PNGase F cleaves
complex, hybrid, and high-mannose glycosylations. The lane
loaded with WT ClC-5 showed specific bands of B90 and
B100 kDa. The 90 kDa band of WT ClC-5 was sensitive to
Endo H, whereas the 100 kDa band was not (Figure 3b). This
indicates that the 90 kDa protein contains high-mannose
glycosylation and is retained in the endoplasmic reticulum,
whereas the 100 kDa protein contains complex glycosylation.
In contrast, the 100 kDa band was sensitive to PNGase F
(Figure 3b). The Endo H and PNGase F digestion showed that
the core protein migrated with an apparent molecular size of
83 kDa (Figure 3b). Similar treatments revealed that the
G212A mutant displayed the WT ClC-5 complex glycosylation
(Figure 3c). In contrast, only core-glycosylation was observed
with the C219R mutant (Figure 3c). The G179D, L200R,
S203L, C221R, L469P, and R718X mutants also showed core-
glycosylation (data not shown).
Thus, abolition of conduction and surface expression for the
G179D, L200R, S203L, C219R, C221R, L469P, and R718X
mutants are compatible with impaired N-glycosylation, which is
likely to result in rapid degradation of the products within the cell.
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Figure 2 |Current/cell surface expression relationship for WT
and mutant ClC-5. Currents at þ 100mV are from the same data
as in Figure 1a. For cell surface expression, the values (measured
in RLU, relative light units) were normalized to those of WT ClC-5
in the same batch of oocytes. Each column represents the
mean±s.e.m. for at least six oocytes for current recordings, and at
least 60 oocytes from three different batches of oocytes for the
surface expression. *Po0.001 for the difference between WT or
mutants ClC-5 vs NI. xPo0.001 for the difference between NI or
mutants ClC-5 vs WT ClC-5. NI, non-injected oocytes; WT,
wild-type oocytes.
kDa
kDa kDa
WT NI G1
79
D
L2
00
R
S2
03
L
G2
12
A
C2
19
R
C2
21
R
L4
69
P
R7
18
X
100 100
75 75
OOCYTES
CLC-5 HA WT
G212A
Ctl CtlH HF F
H
+ +– –
F C219R
GAPDH
CIC-5
100
75
37
Figure 3 |Western blot analysis of WT and mutants ClC-5.
(a) Total cell lysates were isolated from NI and injected oocytes.
(b) and (c) Total cell lysates were isolated from oocytes injected
with WT or mutants ClC-5. Some preparations were treated with
PGNase F (F) and Endo H (H). Ctl, Control; NI, non-injected
oocytes; WT, wild-type oocytes. Data are typical results for 40
oocytes from three different batches of oocytes.
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To further document the subcellular localization of WT
and mutants ClC-5, we performed confocal microscopy
imaging of indirect immunofluorescence in transiently
transfected HEK293 cells. As shown in Figure 4, WT ClC-5
staining colocalized with biotinylated cell-surface proteins
and with the early endosomes marker EEA1. A weak
colocalization between WT ClC-5 and the endoplasmic
reticulum marker calnexin was also observed. Similarly, the
G212A mutant colocalized with biotinylated cell-surface
proteins and EEA1. To further confirm plasma membrane
expression for WT ClC-5 and the G212A mutant, we carried
out surface biotinylation experiments. No significant differ-
ence could be detected in the surface fraction containing WT
ClC-5 compared with the G212A mutant (Figure 5). Interest-
ingly, in contrast to the total cell lysates, the biotinylated
protein fraction contained only the complex-type glycosy-
lated fraction of ClC-5, indicating that the plasma membrane
ClC-5 component is complex glycosylated. In contrast, the
G179D, L200R, S203L, C219R, C221R, L469P, and R718X
mutants were retained in the endoplasmic reticulum
compartment, as shown by their colocalization with the
endoplasmic reticulum marker calnexin, and were excluded
from the plasma membrane and the early endosomes
(Figure 4). Surface biotinylation experiments also showed
that the C219R mutant was excluded from the surface
biotinylated protein fraction (Figure 5). The G179D, L200R,
S203L, L469P, and R718X mutants were also excluded from
the apical biotinylated protein fraction (data not shown). As
a whole, abolition of conduction and surface expression of
these mutants are compatible with their endoplasmic
reticulum retention, which is likely to result in rapid
degradation of the products within the cell.
DISCUSSION
Here, we have explored the functional effects of five novel
CLCN5 mutations found in patients with Dent’s disease,
including four missense mutations (G179D, S203L, G212A,
and L469P) and one nonsense mutation (R718X), plus three
previously published missense mutations (L200R, C219R and
C221R).
The G179D, L200R, S203L, C219R, C221R, L469P, and
R718X mutants displayed a defective protein surface expres-
sion, electrical activity, and lacked the complex glycosylation
showed by WT ClC-5. Our immunocytochemical analysis in
HEK293-transfected cells revealed that these mutants are not
detected at the cell surface because they are retained in the
Merge
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Figure 4 | Immunocytochemical localization of WT and mutants ClC-5 in HEK293-transfected cells. ClC-5 expression was detected by
green fluorescence. Organelles were stained with one of three markers: biotin (plasma membrane), EEA1 (early endosomes), calnexin
(endoplasmic reticulum) and were detected by red fluorescence. The yellow fluorescence indicates that both proteins are present. Scale bars,
7mm. WT, wild type.
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endoplasmic reticulum, probably due to improper folding.
As a consequence, they may be subjected to early degradation
by quality control mechanisms thus accounting for their
reduced protein expression and their core-glycosylation form.
As far as we are aware, only one CLCN5 mutation is known
to result in impaired N-glycosylation, the G333R mutation
located in the J helix.23 The authors speculated that the
mutation may induce a disruption of the interface between
the homodimers,24,25 and that would in turn lead to the
formation of misfolded proteins and rapid degradation.
These data do not help to explain our findings, because the
five missense mutations are located quite some distance from
the transporter interface. However, it is interesting to note
that apart from G179D and R718X they are all located in
a-helices (Figure 6). These mutations may significantly affect
the stability of the a-helices, thus enhancing protein
degradation. Lack of complex glycosylation is usually
observed in mutant proteins not reaching the plasma
membrane. This is the case for instance for the NCC
protein-carrying mutations for Gitelman syndrome.26,27
However, Schmieder et al.28 studying X. laevis ClC-5 with
mutations on N-glycosylation sites observed that a significant
fraction of non-glycosylated X. laevis ClC-5 mutants escaped
from endoplasmic reticulum retention and was targeted to
the plasma membrane.
Our results for the R718X mutant, which predict a loss of
28 amino acids from the C terminus and a deletion of a part
of CBS2 domain, are in sharp contrast with previous findings
reported for the Y617X, R648X, and R704X ClC-5 mutants
that affect the CBS1 and CBS2 domains. Residual activity was
found for the R648X mutant,18 but not for the Y617X and
R704X mutants.21,29 However, the last three mutants were all
found to be targeted to the cell surface, with an increase in
surface expression for the R648X mutant.18,30,31 Our findings
raise the possibility that the R718X mutation may interfere
with the proper folding of the C terminus of ClC-5 that is
necessary to pass the quality controls of the endoplasmic
reticulum.
In contrast to the previous mutants, the G212A mutant
underwent further processing and appeared to be modified
into complex glycosylated forms, and trafficked to the cell
surface and to the early endosomes, like WT ClC-5.
This mutant displayed reduced currents with normal cell
surface expression. The G212A mutation is located at the
beginning of helix F (Figure 6).24,25 It directly follows the
‘gating glutamate’ which is responsible for coupling the Cl
flux to the Hþ counter-transport in ClC Cl/Hþ exchan-
gers.3,4,32 Neutralization of the ‘gating glutamate’ converted
EcClC-1, ClC-4, and ClC-5 into pure anion conductances
and abolished the strong outward rectification of ClC-4 and
ClC-5.3,4,32 Here, we demonstrated that the G212A mutation
reduced the electrical activity without abolishing the outward
rectification. Several mechanisms can account for the reduced
current amplitudes: the mutation could eliminate the Hþ
coupling to Cl, the mutant protein could show lower
transport rates, the stoichiometry of Cl/Hþ coupling could
be modified and the probability of the mutant protein of
being in an active state could be affected. Future studies are
needed to examine the specific effects of the G212A
mutation.
By using whole-cell recordings and a vesicular acidifica-
tion assay in HEK–MSR cells expressing ClC-5 pathogenic
mutations, Smith et al.17 recently showed that the R280P
mutation resulted in altered electrical activity, reduced
plasma membrane expression, increased expression in early
endosomes, and enhanced endosomal acidification. To
explain the abnormal decrease of intraluminal pH, the
authors raised the hypothesis that an accumulation of the
mutant protein in early endosomes would ideally support
and enhance endosomal acidification. Here, we have shown
that the G212A mutant also displayed reduced electrical
activity like the R280P mutant. However, because the G212A
mutant trafficked normally to the plasma membrane and
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Figure 5 |Cell surface expression of WT and mutant ClC-5 in
HEK293-transfected cells. (a) Western blot analysis of the surface
biotinylated protein fraction (S) or total cell lysates (T).
(b) Relative quantification of cell surface expression of WT and
mutant ClC-5. Densitometric analysis of total and cell surface
ClC-5 is shown as the ratio of biotinylated surface proteins to total
cells lysates quantified by densitometry. Each column represents
the mean±s.e.m. from five experiments. UT, untransfected cells;
WT, wild type.
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Figure 6 |Amino acid sequence alignment of several ClCs
showing the positions of the CLCN5 mutations characterized
in this study. The conserved regions are shown in bold and
highlighted in gray. Mutations are shown above the sequences.
The alignment was performed using BioEdit.
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early endosomes like WT ClC-5, further investigations are
required to determine the possible effects of the mutation on
the intraluminal pH.
In conclusion, two types of ClC-5 mutants can be
distinguished. Type-I mutants are properly targeted to the
plasma membrane and early endosomes, but with reduced
electrical activity (G212A). Type-I mutants are complex
glycosylated. Type-II mutants fail to induce currents, because
of defective processing in N-glycosylation resulting in
endoplasmic reticulum retention (G179D, L200R, S203L,
C219R, C221R, L469P, and R718X).
MATERIALS AND METHODS
DNA sequence analysis of the CLCN5 gene
Peripheral blood samples were obtained and genomic DNA was
extracted by standard methods. The coding exons (2 to 12) and
intron–exon junctions were amplified with CLCN5-specific primers
described elsewhere using PCR amplification.33 We carried out direct
sequencing using the dioxy chain termination method on an automated
Perkin Elmer/Applied Biosystems (Foster City, CA, USA) Division
373A Stretch DNA capillary sequencer, and evaluated sequences with
Sequencher software (Gene Codes, Ann Arbor, MI, USA).
Molecular biology
ClC-5 mutants were synthesized from human wild-type ClC-5
extracellularly HA-tagged and subcloned either into the pTLN
expression vector for expression in X. laevis oocytes or into the
peGFP expression vector for expression in HEK293 cells. The coding
sequence for GFP in the peGFP vector have been substituted for
those of WT or mutant ClC-5. Site-directed mutagenesis was
performed with the Quickchange site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA). All constructs were fully sequenced.
Expression in X. laevis oocytes
Capped cRNA were synthetized in vitro from wild-type and mutants
ClC-5 expression vectors using the SP6 mMessage mMachine Kit
(Ambion, Austin, TX, USA). Defolliculated X. leavis oocytes were
injected with 20 ng of the different cRNAs and were then kept at
17 1C in modified Barth’s solution containing (in m mol): 88 NaCl,
1 KCl, 0.41 CaCl2, 0.32 Ca(NO3)2, 0.82 MgSO4, 10 HEPES, pH 7.4,
and gentamicin (20 mg/ml).
Electrophysiology
Five days after injection, two-electrode voltage-clamp experiments
were performed at room temperature using a TEV-200A amplifier
(Dagan, Minneapolis, MN, USA) and PClamp 8 software (Axon
Instruments, Union City, CA, USA). Currents were recorded in ND96
solution containing (in m mol): 96 NaCl, 2 KCl, 1.5 CaCl2, 1 MgCl2, 5
HEPES, pH 7.4. For pH 5.5 and 6.5, 5 m mol HEPES was replaced by
5 m mol MES. In the iodide substitution experiment, 80 m mol Cl
was replaced by equivalent amounts of I. Currents were recorded in
response to a voltage protocol consisting of 20 mV steps from –100 mV
to þ 100 mV during 800 ms from a holding potential of –30 mV.
Surface labeling of oocytes
Experiments were essentially performed as previously described,34
using a rat monoclonal anti-HA antibody (3F10, Roche Diagnostics,
Meyland, France) as primary antibody and a peroxidase-conjugated
goat anti-rat antibody (Jackson ImmunoResearch, West Grove, PA,
USA) as secondary antibody. Chemiluminescence was quantified in a
Turner TD-20/20 luminometer (Turner Designs, Sunnyvale, CA, USA)
by placing individual oocytes in 50ml of SuperSignal Elisa Femto
Maximum Sensitivity Substrate Solution (Pierce, Rockford, IL, USA).
Cell culture and transfection
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium
(GIBCO, Invitrogen, CA, USA) supplemented with 10% fetal bovine
serum, penicillin (100 U/ml), and streptomycin (100 mg/ml) at 37 1C
in 5% CO2. The cells were transiently transfected using Fugene 6
according to the manufacturer’s instructions (Roche Diagnostics).
Immunocytochemistry
Transfected HEK293 cells were plated on 12 mm diameter Petri
dishes. Cells were then fixed in 4% paraformaldehyde and
permeabilized with 0.3% Triton. Nonspecific binding sites were
blocked with 16% goat serum solution. Primary antibodies were
mouse anti-HA (Sigma, St Louis, MO, USA), rabbit anti-EEA1
(Sigma, St Quentin Fallavier, France), rabbit anti-calnexin (Stress-
gen, Ann Arbor, MI, USA). FITC-conjugated goat anti-mouse
(Jackson ImmunoResearch), TRITC-conjugated goat anti-rabbit
(Jackson ImmunoResearch), or Cy5-conjugated streptavidin (Sigma)
were added to the cells as secondary antibodies. Labeled cells were
analyzed with a Zeiss LSM 510 confocal laser-scanning microscope.
Surface biotinylation of HEK293 cells
Forty-eight hours after transfection, cells were placed on ice and
rinsed twice with a cold rinsing solution containing PBS, 100 mmol
CaCl2, and 1 m mol MgCl2. Cells were then incubated at 4 1C for 1 h
with PBS and 1.5 mg/ml NHS-biotin (Pierce, Rockford, IL, USA).
They were incubated in quenching solution containing 0.1% BSA
diluted in PBS and rinsed three times with the rinsing solution.
After lysis in a solution containing 20 m mol Tris-HCl, 2 mM EDTA,
2 m mol EGTA, 30 m mol NaF, 30 mM NaPPi, 1% Triton, 0.1% SDS
and a protease inhibitor mix (Complete, Roche Diagnostics), equal
amount of proteins were precipitated at 4 1C overnight using
streptavidin–agarose beads (Pierce). Samples were then centrifuged
at 2500 g during 2 min at 4 1C with TLB solution containing
50 m mol Tris-HCl, pH 7.4, 100 m mol NaCl, 5 m mol EDTA, and
the protease inhibitor mix.
Protein isolation
Total cell lysates were isolated from oocytes after homogenization of
the cells in an ice-cold solution containing (in m mol): 250 sucrose,
0.5 EDTA, 5 Tris-HCl, pH 7.4, and a protease inhibitor mix
(Complete, Roche Diagnostics). Samples were centrifuged three
times at 500 g for 2 min to remove yolk platelets. Protein
concentration in the resulting supernatant was quantified using a
protein assay quantification kit (BCA Protein Kit Assay, Pierce).
Digestion of proteins with N-glycosidase F (PNGase F) and
endoglycosidase H (Endo H) (New England Biolabs, Ipswich, MA,
USA) was performed according to the protocol provided by the
manufacturer.
For the isolation of total cell lysates from HEK293, cells were
incubated 10 min on ice with the lysis solution. Samples were
centrifuged at 13,000 r.p.m. for 5 min. Protein concentration in the
supernatant was quantified using the protein assay quantification kit.
Western blot analysis
The proteins were separated on an 8% SDS-PAGE gel and
transferred to PVDF membranes. Primary rat anti-HA monoclonal
1004 Kidney International (2009) 76, 999–1005
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antibody (3F10, Roche Diagnostics), rabbit anti-GAPDH mono-
clonal antibody (Abcam, Cambridge, UK) and secondary perox-
idase-conjugated goat anti-rat antibody (Jackson ImmunoResearch)
and anti-rabbit (Promega, Madison, WI, USA) were diluted in TBS-
blocking solution. Detection was performed using the ECL western
blotting Substrate (Pierce).
Statistics
Results are shown as mean±s.e.m. n indicates the number of
experiments. Significance was analyzed by a paired Student’s t-test.
Po0.05 was considered significant.
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